Novamed Inc is a recently established new generation pharmaceutical company headquartered in Shanghai, China. Part of Novamed Inc's commercial model is to facilitate clinical development work in China, India and South Africa on behalf of international companies that today are not present or focused in these geographies. Its partner companies are hoping to capitalize on the cost arbitrage opportunities as well as speed of doing clinical research in India, China and South Africa.

The company, as part of its business model, is seeking to secure the services of a professional CRO based in India. Veeda Clinical Research (Veeda) is a world class global CRO with offices and facilities in both the UK as well as that of India. The proposed agreement is designed to allow for Novamed to seek development projects from Japan, the US and Europe which in turn will be delivered through Novameds development network in India, China and South Africa.

“The relationship with Veeda represents an important development in the Novamed development strategy. Leveraging the skills and arbitrage opportunities that India and China offer the international company, places the two companies in a unique position globally " Mark Lotter - CEO , Novamed Pharmaceuticals Inc

"I am very excited by the opportunity of servicing the new clients that this relationship brings. It will allow Veeda to further leverage its unique offering: Our rich experience in Clinical Development and Biometrics from Europe and our cost effectiveness and patient recruitment efficiency from India" Apurva Shah - Managing Director, Veeda Clinical Research Pvt. Ltd.